BMO Capital analyst Ryan Thompson maintains SSR Mining (NASDAQ:SSRM) with a Outperform and lowers the price target from $26 to $25.
AstraZeneca Announced Enhertu Recommended for Approval in the EU by CHMP for Patients with HER2-low Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo's Enhertu is the first HER2-directed therapy to demonstrate a significant survival benefit vs. chemotherapy in this patient population.